Description: N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system; and Nanomerics Limited to produce and test two candidate formulations using the Nuvec delivery system. N4 Pharma Plc is based in London, the United Kingdom.
Home Page: www.n4pharma.com
N4P Technical Analysis
60 Gracechurch Street
London,
EC3V 0HR
United Kingdom
Phone:
44 1332 690061
Officers
| Name | Title |
|---|---|
| Mr. Nigel James Theobald | Founder, CEO & Exec. Director |
| Dr. David Templeton | Exec. Director & Technical Director |
| Mr. Luke Sebastian Cairns | Exec. Director |
| Rob Harris | Head of CMC Devel. |
| Dr. Andrew Leishman | Consultant |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4132 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |